Dropdown

EE - Estonia
All companies
    All persons

      Search word:

      Field/EMTAK

      MEDFILES OÜ

      Media page and news feed
      ?
      ?
      profile visits
      1,664
      ?
      company tracker
      18
      This company's branding has already reached 1,664 peopleand his is followed by 18 Storybook users.On average, the company has been rated 4.5 points.but there is

      MEDFILES OÜ current status

      2184939_andmerobot_99391772_a_xl.jpg
      Andmerobot
      Did you notice typos in the article?

      Dropdown

      This company's branding has already reached 1,664 peopleand his is followed by 18 Storybook users.On average, the company has been rated 4.5 points.but there is no comment.

      Tegevusaruanne 2025

      Üldinfo ja põhitegevus

      Medfiles OÜ kontserni (edaspidi: Kontsern) põhitegevusalaks on ravimite, meditsiiniseadmete, toidulisandite ja kosmeetikatoodete registreerimise ning ravimiohutusega seonduvate teenuste osutamine.

      Kontserni kuulub emaettevõte Medfiles OÜ ning kaks 100%-list tütarettevõtet: Medfiles SIA Lätis ja Medfiles UAB Leedus. Medfiles OÜ ainuomanik on Soome ettevõte Medfiles OY, mis kuulub alates 2017. aastast Tokyo börsil noteeritud kontserni WDB Holdings Co., Ltd.

      Majandustegevuse ülevaade 2025. aastal jätkus stabiilne koostöö rahvusvaheliste ravimitootjate ja arendusettevõtetega. Kontsern pakkus regulatiiv- ja ohutusalaseid teenuseid nii Baltimaades kui ka mujal Euroopas.

      Aasta oli Kontserni jaoks edukas – müügitulu ulatus 1,31 miljoni euroni, kasvades võrreldes 2024. aastaga 11%. Majandusaasta lõppes 113 504 euro suuruse puhaskasumiga.

      Juhtimine ja personal

      Medfiles OÜ juhatus on üheliikmeline, juhatuse liige on Norifumi Ninokata. Tütarettevõtete juhtorganite koosseis on järgmine:

      Medfiles SIA (Läti): juhatuse liikmed Norifumi Ninokata ja Santa Zeibote.

      Medfiles UAB (Leedu): juhatuse liige Norifumi Ninokata.

      Medfiles OÜ juhatuse liikmele sarnaselt 2024. aastale tasusid ei makstud ning ei ole ette nähtud ka muid olulisi soodustusi ega hüvitisi.

      Dividendipoliitika

      Dividende makstakse vastavalt osanike otsustele ja ettevõtte pikaajalistele strateegilistele eesmärkidele.

      Peamised suhtarvud 2025. ja 2024. aasta kohta:

      Näitaja 2025 2024

      Müügitulu (EUR) 1 309 023 1 184 020

      Tulu kasv (%) 10,56 1,33

      Ärikasumimäär (%) 8,66 8,90

      Puhaskasum (EUR) 113 504 113 077

      Kasumikasv (%) 0,38 55,15

      Puhasrentaablus (%) 8,67 9,55

      Lühiajaliste kohustuste 7,99 7,54 kattekordaja (kordades)

      Maksevalmiduse kordaja 6,06 5,41 (kordades)

      ROA (%) 12,45 14,34

      ROE (%) 14,22 16,51

      Suhtarvude arvutamisel kasutatud valemid:

      Comments (0)

      Are you sure you want to delete this article?

      Dropdown

      all articles
      MEDFILES OÜ / Andmerobot

      How to get health claims approved in the eu/us

      Health claims are statements made on food or supplement labels that describe the relationship between a food component and improved health or reduced risk of di
      ssb.ee
      Health claims are statements made on food or supplement labels that describe the relationship between a food component and improved health or reduced risk of disease. These claims are heavily regulated to ensure consumer protection and scientific accuracy. The European Union and the United States have distinct regulatory frameworks for health claims. In the EU, the European Food Safety Authority (EFSA) is responsible for evaluating the scientific evidence behind health claims, while in the US, the Food and Drug Administration (FDA) oversees the approval process. Understanding these
      MEDFILES OÜ / Andmerobot

      Navigating clinical trials for medical devices

      Clinical trials are a critical phase in the development of medical devices, ensuring that new products are safe and effective for patient use. These trials prov
      ssb.ee
      Clinical trials are a critical phase in the development of medical devices, ensuring that new products are safe and effective for patient use. These trials provide the scientific evidence necessary to satisfy regulatory requirements and gain market approval. Unlike pharmaceutical trials, medical device trials often involve additional complexities such as device-operator interactions, varying patient anatomies, and the iterative nature of device development. Regulatory Framework for Medical Device Trials Regulatory bodies such as the FDA in the United States, EMA in Europe, and others
      MEDFILES OÜ / Andmerobot

      The future of algae-based foods in europe

      Algae, a diverse group of photosynthetic organisms, is emerging as a sustainable superfood. Rich in proteins, vitamins, minerals, and essential fatty acids, alg
      ssb.ee
      Algae, a diverse group of photosynthetic organisms, is emerging as a sustainable superfood. Rich in proteins, vitamins, minerals, and essential fatty acids, algae presents a promising alternative to traditional food sources. With the ability to grow in a variety of environments, algae's versatility makes it a valuable asset in the food industry. Europe has seen a growing interest in algae-based foods, with several startups and established companies exploring its potential. The market is still in its nascent stages, but with increasing awareness and demand, algae-based foods are poised for

      File a complaint

      Choose the comment attribute that you think it contains:

      False information
      Spam
      Hate speech
      Terrorism
      Other

      You want to report an inappropriate comment.

      Are you sure?

      Are you sure you want to delete this article?

      Loader

      Loader

      App Ad

      Scorestorybook Chrome extension

      The Storybook extension tells you which company's website you are currently on and how reliable that company is today. download extension

      See the background of the caller! Storybook App brings you direct contacts for 400,000 Estonian companies and individuals (managers, officials). The data is enriched with solvency and financial information.

      We value your privacy

      We use cookies to improve your browsing experience, provide personalized ads or content, and analyze our traffic. By clicking "allow all", you agree to our use of all cookies.